doi:10.19982/j.issn.1000-6621.20240262

Abstract

CLC Number:

Figures/Tables 1

References 22

[1]	付亮, 邓国防. MDR-Chin研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景. 中国防痨杂志, 2024, 46(1):18-22. doi:10.19982/j.issn.1000-6621.20230325.
[2]	初乃惠, 聂文娟. 浅谈耐药结核病的全口服治疗方案. 中华传染病杂志, 2020, 38(7):393-396. doi:10.3760/cma.j.cn311365-20200318-00339.
[3]	张玄, 李燕明. 喹诺酮类抗菌药物在呼吸系统感染性疾病治疗中的地位. 临床药物治疗杂志, 2019, 17(7):17-22. doi:10.3969/j.issn.1672-3384.2019.07.005.
[4]	CHINET数据云. CHINET 2022年全年细菌耐药监测结果[EB/OL].[2023-02-18]. http://www.chinets.com/Document/Index?pageIndex=0#.
[5]	Wu S, Yang Y, Guo Y, et al. Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China. Eur J Clin Microbiol Infect Dis, 2021, 40(11):2271-2283. doi:10.1007/s10096-021-04278-3.
[6]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10):733-749. doi:10.3760/cma.j.issn.1001-0939.2019.10.006.
[7]	中华医学会结核病学分会. 抗结核药物超说明书用法专家共识(2023年更新版). 中华结核和呼吸杂志, 2023, 46(11):1085-1102. doi:10.3760/cma.j.cn112147-20230809-00062.
[8]	周龙, 赵峰, 李双. 莫西沙星与左氧氟沙星联合常规用药方案治疗耐多药肺结核的临床效果比较. 临床合理用药杂志, 2022, 15(20):15-18. doi:10.15887/j.cnki.13-1389/r.2022.20.005.
[9]	冯广伟, 石永传. 西他沙星治疗肺炎的药代动力学及其相关机制研究进展. 中国处方药, 2024, 22(5):171-175. doi:10.3969/j.issn.1671-945X.2024.05.051.
[10]	张海晴, 陈效友, 周冬青, 等. 结核分枝杆菌gyrA基因突变与氟喹诺酮类药物体外最低抑菌浓度的关系. 实用临床医药杂志, 2021, 25(14):4-8,14. doi:10.7619/jcmp.20210716.
[11]	Kong Y, Geng Z, Jiang G, et al. Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China. Heliyon, 2023, 9(11): e21216. doi:10.1016/j.heliyon.2023.e21216.
[12]	Sato K, Tomioka H, Sano C, et al. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. J Antimicrob Chemother, 2003, 52(2): 199-203. doi:10.1093/jac/dkg343.
[13]	Tomioka H, Sato K, Kajitani H, et al. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother, 2000, 44(2):283-286. doi:10.1128/AAC.44.2.283-286.2000.
[14]	Yi L, Aono A, Chikamatsu K, et al. In vitro activity of sitafloxacin against Mycobacterium tuberculosis with gyrA/B mutations isolated in Japan. J Med Microbiol, 2017, 66(6): 770-776. doi:10.1099/jmm.0.000493.
[15]	汪阿鹏, 冯连顺. 氟喹诺酮类抗菌药的最新研究进展. 国外医药(抗生素分册), 2019, 40(3):171-179. doi:10.3969/j.issn.1001-8751.2019.03.002.
[16]	孙海林, 任卫聪, 尚媛媛, 等. 结核分枝杆菌gyrA和gyrB基因突变与莫西沙星耐药水平关系. 中国医学前沿杂志(电子版), 2023, 15(10):67-72. doi:10.12037/YXQY.2023.10-10.
[17]	World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[18]	李相鸿, 辛玉霞, 邵静, 等. 富马酸西他沙星注射液在中国志愿者体内的耐受性与药动学. 中国新药杂志, 2023, 32(7):712-718. doi:10.3969/j.issn.1003-3734.2023.07.009.
[19]	黄国宁, 邓为上, 吴君琳, 等. 西他沙星治疗肺炎的疗效和安全性的系统评价和Meta分析. 今日药学, 2022, 32(9):694-698. doi:10.12048/j.issn.1674-229X.2022.09.010.
[20]	中国防痨协会. 耐药结核病化学治疗指南(2009). 中国防痨杂志, 2010, 32(4):181-198.
[21]	黄海荣, 于霞, 姜广路, 等. 利奈唑胺治疗耐多药结核病的初步评价. 中国防痨杂志, 2011, 33(5):275-279.
[22]	Saito H, Tomioka H, Sato K, et al. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother, 1994, 38(12): 2877-2882. doi:10.1128/AAC.38.12.2877. pmid: 7695276

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 22

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[2]	Li Min, Yao Yushan, Qiao Haixia, Lei Hong. Association between pulmonary tuberculosis and the gut microbiota: treatment strategies [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 520-526.
[3]	Song Yunlin, Buzukela Abuduaini, Wang Guirong, Zhang Jiyuan, Lu Xiaobo. Research progresses on the role and mechanism of calcium-binding protein S100A12 and neutrophil extracellular trap formation in lung injury of severe pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 513-519.
[4]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[5]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Li Leilei, Shi Lei, Wang Lin, Li Hongwei, Xu Liran, Pang Yu, Song Yanzheng. Clinical characteristics analysis of HIV-infected cases diagnosed with tuberculosis after surgery due to pulmonary nodules [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 266-273.
[8]	Gong Sheng, Wang Ning, Li Dan, Li Gang, Liu Yu, Jiang Liangshuang, Yao Xiaojun. Comparative study of fluorescence staining method and inflation-deflation method for thoracoscopic pulmonary tuberculosis segmentectomy [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 292-297.
[9]	Shi Yuru, Gu Dejian, Wu Jing, Liu Ting, Qin Linghan, Yue Li, Qi Yingjie. Diagnostic value of probe capture-based targeted next-generation sequencing and metagenomic next-generation sequencing for detecting Mycobacterium tuberculosis in bronchoalveolar lavage fluid [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 305-311.
[10]	Song Feier, Mao Yanjun, Xia Qiuyue, Zhou Yang, Lin Huan. The prevalence and influencing factors of post-tuberculosis lung disease: A Meta-analysis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 322-330.
[11]	Yang Haixia, Zhang Xiaoyan, Huang Yi, Li Qiu. Effective and safety of concurrent intensity-modulated radiotherapy and anti-tuberculosis chemotherapy in patients with active pulmonary tuberculosis comorbid with thoracic tumor [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 312-321.
[12]	Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168.
[13]	Wang Dafu, Ma Xiaoxue, Wang Yun, Li Fudong, Rao Wen, Gong Tingting, Li Shijun, Li Jinlan. Analysis of risk factors for patient delay and adverse treatment outcomes among patients with pulmonary tuberculosis and diabetes mellitus in Guizhou Province, 2016—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 201-209.
[14]	Gao Li, Chen Shengyu, Zhang Wenqian, Li Dan, Zhang Guoqin. Investigation on ability of conducting tuberculosis surveillance among four types of high-risk population in Tianjin public hospitals [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 195-200.
[15]	Qiu Yong, Quan Zhuo, Qu Rong, Tian Fajun, Li Meng, Wang Gengsheng, Wang Ya, Guo Mingcheng, Gao Qian. Evaluation of different tuberculosis diagnostic tools for detecting patients in a primary-level clinic in rural China: a real-world retrospective study [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 181-188.